Daridorexant in severe obstructive sleep apnea: effects on sleep-disordered breathing and sleep.
Ingo Fietze, Marie-Laure Boof, Katharina Lederer et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, placebo-controlled crossover trial evaluated the effects of daridorexant on sleep-disordered breathing and sleep in 16 adults with severe obstructive sleep apnea (OSA) without insomnia. The study found no clinically meaningful impact on the apnea/hypopnea index (AHI) or oxygen saturation (SpO2), with treatment differences of -3.7 events/h and -0.12%, respectively. However, daridorexant increased total sleep time by 32.5 minutes compared to placebo.
Key findings
- No clinically meaningful effect on AHI was observed, with a treatment difference of -3.7 events/h.
- No significant change in nocturnal SpO2 was noted, with a treatment difference of -0.12%.
- Daridorexant increased total sleep time by 32.5 minutes compared to placebo.
- Latency to persistent sleep decreased by 10.3 minutes with daridorexant.
Why it matters
Understanding the safety and efficacy of sleep medications in patients with obstructive sleep apnea is crucial, as many individuals with OSA also experience insomnia. This study suggests that daridorexant may be a safe option for improving sleep without worsening respiratory function.